Strikingly, TAM-mediated MYC-ERT2 activation strongly accelerated the growth of EP-MycERT2 tumors treated with AZD8055, resulting in a shortened latency of tumor-specific survival comparable with vehicle-treated controls (Fig. 6, A and B). This evidence concerns the gene MAPK3 and neoplasm.